Efficacy of Mutilayered Fresh Amnoitic Membrane Transplantation in Resistant Fungal Keratitis

Sponsor
Al-Azhar University (Other)
Overall Status
Completed
CT.gov ID
NCT06070883
Collaborator
(none)
26
1
1
21
1.2

Study Details

Study Description

Brief Summary

Corneal infection or infectious keratitis (IK) is the most common cause of corneal blindness worldwide, particu-larly in the developing countries1. The incidence was estimated at 2.5-799 per 100,000 population/year. It is a painful and potentially blinding ocular emergency that often requires hospital admission for intensive medical and/or surgical treatment. Depending on the geographical and temporal variations and population-based risk factors (e.g. agricultural practice, trauma, use of contact lens and others), bacteria and fungi have been shown to be the main causative microorganisms for IK, followed by viruses, parasites and polymicrobial infection. Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix (15).

It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. To date, a number of studies have evaluated the benefit of AMT for treating active IK, though the majority of them were of small case series or case reports. In clinical practice, AMT is usually reserved as a second-line therapy in IK, mainly to promote cornea healing in non-healing ulcer after the sterilization phase.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Amniotic membrane transplantation
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Mutilayered Fresh Amnoitic Membrane Transplantation in Resistant Fungal Keratitis
Actual Study Start Date :
Jan 1, 2022
Actual Primary Completion Date :
Sep 8, 2023
Actual Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Amniotic membrane

Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix.It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others

Procedure: Amniotic membrane transplantation
Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.

Outcome Measures

Primary Outcome Measures

  1. Corneal Pain [Baseline]

    it will be meaured by the Visual analouge scale

  2. Corneal Pain [one month post operative]

    it will be meaured by the Visual analouge scale

  3. Corneal Pain [three months post operative]

    it will be meaured by the Visual analouge scale

  4. Size of the ulcer [Baseline]

    it will be meaured in mellimeter

  5. Size of the ulcer [one month post operative]

    it will be meaured in mellimeter

  6. Size of the ulcer [three months post operative]

    it will be meaured in mellimeter

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Size more than 5 mm.

  • Deep ulcers i.e. > 50% stromal thickness.

  • Located within 3mm of the visual axis.

  • Patients with descemetoceles and corneal perforations will also be included

Exclusion Criteria:
  • Corneal ulcers of size < 5mm depth < 50%

  • Associated glaucoma

  • Associated chronic dacryocystitis

  • Ulcers with entropion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ehab tharwat Damieta New Damietta Egypt 34517

Sponsors and Collaborators

  • Al-Azhar University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ehab Tharwat, Principal investigator, Al-Azhar University
ClinicalTrials.gov Identifier:
NCT06070883
Other Study ID Numbers:
  • Resistant fungal keratitis
First Posted:
Oct 6, 2023
Last Update Posted:
Oct 6, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 6, 2023